The increasing interest in developing Artificial Intelligence applications in the medical domain, suffers from the lack of high-quality dataset, mainly due to privacy-related issues. Moreover, the recent rising of Multimodal Large Language Models (MLLM) leads to a need for multimodal medical datasets, where clinical reports and findings are attached to the corresponding CT or MR scans. This paper illustrates the entire workflow for building the data set MedPix 2.0. Starting from the well-known multimodal dataset MedPix\textsuperscript{\textregistered}, mainly used by physicians, nurses and healthcare students for Continuing Medical Education purposes, a semi-automatic pipeline was developed to extract visual and textual data followed by a manual curing procedure where noisy samples were removed, thus creating a MongoDB database. Along with the dataset, we developed a GUI aimed at navigating efficiently the MongoDB instance, and obtaining the raw data that can be easily used for training and/or fine-tuning MLLMs. To enforce this point, we also propose a CLIP-based model trained on MedPix 2.0 for scan classification tasks.

Background: Graph Neural Networks (GNN) have emerged in very recent years as a powerful tool for supporting in silico Virtual Screening. In this work we present a GNN which uses Graph Convolutional architectures to achieve very accurate multi-target screening. We also devised a hierarchical Explainable Artificial Intelligence (XAI) technique to catch information directly at atom, ring, and whole molecule level by leveraging the message passing mechanism. In this way, we find the most relevant moieties involved in bioactivity prediction. Results: We report a state-of-the-art GNN classifier on twenty Cyclin-dependent Kinase targets in support of VS. Our classifier outperforms previous SOTA approaches proposed by the authors. Moreover, a CDK1-only high-sensitivity version of the GNN has been designed to use our explainer in order to avoid the inherent bias of multi-class models. The hierarchical explainer has been validated by an expert chemist on 19 approved drugs on CDK1. Our explainer provided information in accordance to the docking analysis for 17 out of the 19 test drugs. Conclusion: Our approach is a valid support for shortening both the screening and the hit-to-lead phase. Detailed knowledge about the molecular substructures that play a role in the inhibitory action, can help the computational chemist to gain insights into the pharmacophoric function of the molecule also for repurposing purposes.